Friday, 13 July 2012

A Transatlantic screening debate

Much as US culture eventually wings its way over to the UK, and extends a huge influence over everything from gastronomy (a personal thank you for cheeseburgers and fries) to advertising and television, there are some areas on which we differ.

The approach to the PSA test, still the cornerstone of prostate cancer diagnosis across the globe, for want of a more reliable test, was until recently one of these points of difference. The USA has traditionally used the test as the basis of a screening programme.

The UK, taking a more cautious approach in the face of evidence of the risks of over-treatment as a result of screening, has encouraged men to make a choice through discussion with their GP about whether the test is right for them.

Now, the US is changing tack, which has sparked polarised debate in the US. The USPSTF* has revised its position even though the latest European trial results have strengthened the argument for screening by showing that its impact on reducing deaths from the disease may be higher than originally thought. The powerful pro-screening lobby, encompassing a broad range of prominent politicians and clinicians, is now occupying defensive territory - and making a lot of noise about the Task Force’s decision.

Interestingly, it is a position which isn’t binding. Patients and clinicians are asking, very often through the US media, ‘where do we go from here?’. Some doctors are adamant they will continue to screen their patients, with others less certain how to proceed. Barack Obama’s Health Secretary, Kathleen Sebelius, prompted by the anger generated by the USPSTF’s recommendation, has even gone as far as to put out a statement distancing the US Government from the Task Force to underline the fact that the body ‘does not set health policy’. This resulting furore shows how difficult it is to have this debate in the US public arena, given the very strong emotions involved. Emotive stories of people who believe they have benefitted from screening, are very powerful, and cloud even research-based statistics.

From a UK perspective, we can only agree with the Task Force’s decision, mirroring as it does our position and given the clear drawbacks of population-wide screening. Yet the unambiguous line here, even if it is controversial in some quarters, has its drawbacks. Debate around the test is at best sporadic, rearing its head with new research or a celebrity diagnosis. The interim silence can read as a quiet acceptance of the status quo. Men being expected to make a decision themselves around a flawed test, which could have far-reaching consequences for their life and health, can hardly be desirable, especially when we know some GPs have a bias. At least the divergent view points in the US, and the prominence of the debate, is showing that men deserve better. The volume is good. Maybe the discourse needs to be different - should it not be around research into a new generation test. One, which does not run the risk of ending a man’s sex life and causing incontinence unnecessarily. This is where our own research strategy is leading.

I am using this American-themed post to introduce a link to Dan Zenka’s blog. It chronicles not only his reaction to emerging prostate cancer-related issues, from the perspective of his role as Senior Vice President of the Prostate Cancer Foundation, but also his own battle with the disease. We met recently at a conference hosted by our partner Movember in ‘The States’, looking at how we can pool resource and expertise to channel resource effectively into global research priorities. Linking our blogs mirrors this intention to close boundaries. It is a small way of sparking debate and dialogue from a more universal perspective. That is exactly what we need to tackle this disease, a concerted, universal approach to make sure men with prostate cancer get what they need. A new test is the best starting point I can think of.

*US Preventive Services Task Force - an independent group of experts that make recommendations about services such as screening, counselling and preventive medications, in the USA.

Sunday, 1 July 2012

Shaken - And Stirred

Final day, and I think 'Miss Funnypenny' and I would call this mission accomplished as we head back to Britain. As well as smashing our £100,000 fundraising target, alongside Keyline Builders Merchants - we have woken up thousands of men to this disease.

We all made the 10,000 foot assault on Schilthorn, in our 007 finery. There have been some real Bond moments on the way, alpine descents (albeit by cable car, not parachute), cars 'chasing' around mountain bends and the odd dry Martini. There was even a bikini moment, which will clearly rank alongside those immortalised by Ursula Andress and Halle Berry, as my 'Bond Girl' stepped into a two piece and emerged from a lake. Well, it certainly gave the locals an image to remember.

All of this has been done not on 'Her Majesty's Service', but in the name of fighting prostate cancer. There is no Dr No or Goldfinger in this particular adventure. Our 'villain' is a disease which claims way to many lives and the injustice which surrounds it.

Our first mission as Prostate Cancer UK has really crystalised for me why we needed to be more focussed, increase our ambition and raise our voice. Put simply, men deserve better.

The energy Andrew Harrison, CEO of Keyline, and his team have put into this endeavour, which deserves a massive thank you from me, hints at a groundswell of support for this notion, and a willingness to do something about it. Men's health needs to take centre stage, and there is a role to play in bringing all men together to achieve this.

I will be back at 'HQ' this week working with the team to really push those ambitions forward.

In the meantime, thank you to everyone who has sponsored us, a well done to my lovely Bond Girl (I could not have done it without 'her') and, of course, to Keyline Builders Merchants.

I would like to make a final plea for sponsorship. The Thunderball Rally will make a real difference to our real mission.